ADMA Biologics Inc (NASDAQ:ADMA) Stock Has Average Target Price of $18.67 According to Brokerages

ADMA Biologics Inc (NASDAQ:ADMA) has been given a consensus rating of “Moderate Buy” by the six analysts that are covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $18.67.

ADMA has been the topic of several analyst reports. Mizuho reduced their price objective on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Raymond James Financial started coverage on ADMA Biologics in a research note on Wednesday, June 10th. They set an “outperform” rating and a $21.00 target price for the company. Zacks Research upgraded ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 2nd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Monday, September 14th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ADMA. Royal Bank of Canada grew its stake in shares of ADMA Biologics by 448.8% during the first quarter. Royal Bank of Canada now owns 929,326 shares of the biotechnology company’s stock worth $8,373,000 after purchasing an additional 759,984 shares in the last quarter. Bank of America Corp DE raised its stake in ADMA Biologics by 107.5% in the first quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company’s stock valued at $36,019,000 after buying an additional 2,071,338 shares in the last quarter. Louisiana State Employees Retirement System purchased a new stake in ADMA Biologics during the 1st quarter worth about $951,000. Y Intercept Hong Kong Ltd lifted its holdings in ADMA Biologics by 1,508.1% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 1,075,422 shares of the biotechnology company’s stock worth $9,690,000 after buying an additional 1,008,548 shares during the last quarter. Finally, Odyssean LLC acquired a new position in shares of ADMA Biologics during the 2nd quarter worth about $1,042,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Price Performance

Shares of ADMA opened at $10.14 on Monday. The company has a market cap of $2.27 billion, a P/E ratio of 14.49 and a beta of 0.70. ADMA Biologics has a fifty-two week low of $7.21 and a fifty-two week high of $20.46. The company has a quick ratio of 3.81, a current ratio of 6.97 and a debt-to-equity ratio of 0.49. The firm’s 50 day moving average price is $9.52 and its 200 day moving average price is $9.26.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting the consensus estimate of $0.16. The company had revenue of $124.39 million during the quarter, compared to analysts’ expectations of $125.34 million. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The firm’s revenue was up 2.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.14 EPS. On average, research analysts forecast that ADMA Biologics will post 0.78 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc is a commercial biopharmaceutical company focused on developing, manufacturing and marketing plasma-derived biologic products for people with compromised immune systems. The company’s operations include collecting human source plasma, developing therapies from donated plasma and producing specialty immunoglobulin products.

ADMA’s commercial portfolio includes BIVIGAM, an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency, and ASCENIV, an intravenous immune globulin product for patients with primary immunodeficiency diseases.